LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2011, and provided a business update.
“We are on track to report important progress this year with our oncology clinical programs,” said President and Chief Executive Officer Steven A. Kriegsman. “With INNO-206, our tumor-targeting conjugate of the widely used chemotherapeutic agent doxorubicin, we are completing our Phase 1b/2 clinical trial in patients with solid tumors, primarily soft tissue sarcomas (STS), who have failed multiple treatments.
